Evidence map›Paper›PMID 41279431›Full record

ArticlebioRxiv : the preprint server for biology2025

An InDel Genomic Variant within a Bifunctional Super-Enhancer for LINC00636 and CD47 Regulation in Breast Cancer.

Carolina Di Benedetto, Amelia Tsark, Daniza Acenas, Alysia Thach, Anmol Singhal, Valentina Opazo-Mellado, Anthony Rodriguez Lemus, Mustapha El Zeini, Hui Zhang, Catherine Park and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Carolina Di BenedettoDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Amelia TsarkDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Daniza AcenasDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Alysia ThachDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Anmol SinghalDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Valentina Opazo-MelladoCentro Basal Ciencia & Vida, Fundación Ciencia & Vida, Santiago, Chile.
Anthony Rodriguez LemusDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Mustapha El ZeiniDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Hui ZhangDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Catherine ParkDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.
Hugo Gonzalez VelozoCentro Basal Ciencia & Vida, Fundación Ciencia & Vida, Santiago, Chile.
Irving WeissmannInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Paola BetancurDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA.

Funding

Post Baccalaureate Research Opportunity To Promote Equity In Learning (PROPEL).R25GM144250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Ryan D. Hernandez, Todd Nystul · 2022 to 2026
$1.8M
Identification of Novel Gene Regulatory Interactions Driving the Immune Evasion Program Through Transcriptional Activation of CD47 in CancerK22CA226365 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BETANCUR, PAOLA A · 2019 to 2021
$597k
NCI NIH HHS K22 CA226365NIGMS NIH HHS R25 GM144250
6 · The paper itself

Abstract

Highly accessible genomic super-enhancers often drive tumor-promoting programs, yet the impact of genomic variation within these regulatory elements remains unclear. Here, we identified a bifunctional super-enhancer that regulates the expression of cancer-promoting genes LINC00636 and CD47 in breast cancer. We discovered that a common germline insertion variant within the super-enhancer is associated with reduced chromatin accessibility at the super-enhancer locus. Deletion of the insertion in breast cancer cells increased chromatin accessibility, leading to upregulation of LINC00636 and CD47, enhanced resistance to nutrient-deprivation-induced apoptosis (mediated by CD47), activation of senescence (driven by elevated LINC00636), delayed cell death, and reduced infiltration of CD80

Indexed as

breast cancerCD47genomic variationLINC00636Super-enhancer

Identifiers

PMID41279431
PMCPMC12637730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.